"SILVER SPRING, MD â€” The US Food and Drug Administration (FDA) is warning of several treatment-related serious adverse events in association with implantable left ventricular assist devices (LVADs) in heart-failure patients.
In a "...
DOSAGE AND ADMINISTRATION
For intravenous infusion only.
Adenoscan should be given as a continuous peripheral intravenous infusion.
The recommended intravenous dose for adults is 140 mcg/kg/min infused for six minutes (total dose of 0.84 mg/kg).
The required dose of thallium-201 should be injected at the midpoint of the Adenoscan infusion (i.e., after the first three minutes of Adenoscan). Thallium-201 is physically compatible with Adenoscan and may be injected directly into the Adenoscan infusion set.
The injection should be as close to the venous access as possible to prevent an inadvertent increase in the dose of Adenoscan (the contents of the IV tubing) being administered.
There are no data on the safety or efficacy of alternative Adenoscan infusion protocols.
The safety and efficacy of Adenoscan administered by the intracoronary route have not been established.
The following Adenoscan infusion nomogram may be used to determine the appropriate infusion rate corrected for total body weight:
|Patient Weight||Infusion Rate mL/min|
This nomogram was derived from the following general formula:
0.140 (mg/kg/min) x total body weight (kg)/ Adenoscan concentration (3mg / mL) = Infusion rate (mL/min)
Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
Adenoscan (adenosine injection) is supplied as 20 mL and 30 mL vials of sterile, nonpyrogenic solution in normal saline.
NDC 0469-0871-20 Product Code 87120
60 mg/20 mL (3 mg/mL) in a 20 mL single-dose, flip-top glass vial, packaged individually and in packages of ten.
NDC 0469-0871-30 Product Code 87130
90 mg/30 mL (3 mg/mL) in a 30 mL single-dose, flip-top glass vial, packaged individually and in packages of ten.
Store at controlled room temperature 15°-30°C (59°-86°F)
Do not refrigerate as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use. Contains no preservative. Discard unused portion.
Product of Germany. Marketed by: Astellas Pharma US, Inc. Northbrook, IL 60062 USA. Manufactured by: Hospira, Inc., Lake Forest, IL 60045 USA. Revised October 2013This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/21/2014
Additional Adenoscan Information
- Adenoscan Drug Interactions Center: adenosine iv
- Adenoscan Side Effects Center
- Adenoscan FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.